News Releases

May 24, 2021
Positive Clinical Data About Axcella’s AXA1665 Candidate for Overt Hepatic Encephalopathy Highlighted in Oral Presentation at DDW 2021
May 11, 2021
Axcella Announces Initiation of EMMPACT℠ Phase 2b Clinical Trial of AXA1125
May 06, 2021
Axcella Reports First Quarter Financial Results and Provides Business Update
Apr 27, 2021
Axcella to Report First Quarter 2021 Financial Results on May 6, 2021
Apr 22, 2021
Axcella Announces Upcoming Oral Presentation at Digestive Disease Week (DDW) 2021
Apr 13, 2021
Axcella Announces AXA1125’s IND Clearance for the Treatment of NASH
Mar 17, 2021
Axcella Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
Mar 10, 2021
Axcella to Report Fourth Quarter and Full Year 2020 Financial Results on March 17, 2021
Mar 03, 2021
Axcella Announces Alison D. Schecter, M.D., as President of R&D
Feb 25, 2021
Axcella Announces Upcoming Presentations at NASH-TAG 2021
Displaying 1 - 10 of 13